Survodutide Research: The GCGR/GLP-1 Dual Agonist and What Its Trials Investigated

What is survodutide (BI 456906)?

What is survodutide? It is a synthetic acylated peptide developed at Boehringer Ingelheim and known in the primary literature by the development code BI 456906. Zimmermann et al. (2022, Molecular Metabolism) describe it as a potent glucagon receptor (GCGR) / GLP-1 receptor (GLP-1R) dual agonist — one molecule, two receptors, neither of them GIP.

That receptor pairing is the entire identity of the compound and the reason it needs its own page rather than a line on a comparison table. It is investigational: it has been examined only within clinical trials and is not approved for human use anywhere. In research catalogues it is supplied as a lyophilized powder for bench work. Everything below describes molecule properties and what published studies looked at.

Discovery and origin: copying oxyntomodulin

The design rationale in the discovery paper is a natural-product argument rather than an engineering one. Oxyntomodulin is a gut peptide that activates both the glucagon and GLP-1 receptors; Zimmermann et al. cite it as the biological precedent for a synthetic molecule with the same two targets. The GCGR/GLP-1R combination was not invented in a laboratory — it was found in physiology and then made durable.

“Durable” is the engineering half: survodutide is described as a potent acylated peptide containing a C18 fatty acid as a half-life-extending principle — the same albumin-binding strategy used across this class (semaglutide a C18 diacid, tirzepatide a C20 diacid), applied to a different backbone. The paper is also notable for its author list: Daniel J. Drucker, one of the original describers of GLP-1 biology, is a co-author.

Reference data

The facts below are drawn from the public chemical record (PubChem CID 171378821) and the discovery literature. Fields that could not be sourced — including the full residue sequence — are omitted rather than estimated.

Mechanism — and how each receptor arm was actually demonstrated

Claiming dual agonism is easy; showing it in a living animal is the interesting part, and it is where survodutide’s literature is genuinely instructive. Each point below is what researchers characterised in model systems, not an effect in any reader:

• GLP-1 receptor (GLP-1R) — the incretin arm, shared with every other molecule in this family. Zimmermann et al. demonstrated in vivo engagement through glucose tolerance, food intake and gastric emptying tests, and supported it with GLP-1R knockout and transgenic reporter mice.
• Glucagon receptor (GCGR) — the distinguishing arm. Because the glucagon receptor is heavily expressed in liver, the authors read its engagement out hepatically: liver nicotinamide N-methyltransferase (NNMT) mRNA expression, plus circulating biomarkers including amino acids and fibroblast growth factor-21 (FGF21).
• A tunable balance between the two — Thomas et al. (2024, Diabetes Obes Metab) describe profiling nineteen dual agonists and selecting among close analogues (BI 456906, BI 456908, BI 456897) that differed in the degree of in-vivo GCGR engagement, measured by hepatic NNMT and plasma FGF21. Survodutide was selected on the basis of what the authors call its balanced dual GCGR/GLP-1R pharmacology.

The mechanistic reason a glucagon arm is added at all, as the discovery paper frames it, is that oxyntomodulin acts through both increased energy expenditure and reduced energy intake — two levers instead of one. That is a description of a scientific hypothesis under study in animal models, not a promise of any result. The cross-class receptor comparison across the incretin family lives on the comparison page; the nearest sibling by receptor pair is mazdutide, which shares the GCGR/GLP-1R design and has a completely different development history.

What the survodutide trials investigated

The clinical literature is best read as three separate questions asked in three different populations, and strictly as what each study examined:

Obesity and type 2 diabetes

• le Roux et al., 2024 (Lancet Diabetes Endocrinol, PMID 38330987) — a randomised, double-blind, placebo-controlled dose-finding phase 2 trial of survodutide in obesity.
• Blüher et al., 2024 (Diabetologia, PMID 38095657) — a randomised trial in people with type 2 diabetes that examined dose–response against placebo and against open-label semaglutide as a comparator arm.

Liver

• Sanyal et al., 2024 (NEJM, PMID 38847460) — a phase 2 randomised trial in metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. This is the arm of the programme that follows directly from the mechanism: if the glucagon receptor is read out through the liver, the liver is a natural place to study the molecule.
• Kaplan et al., 2026 (Nature Medicine, PMID 42252333) — SYNCHRONIZE-MASLD, a randomised, double-blind, placebo-controlled phase 3 trial in adults with obesity and metabolic dysfunction-associated steatotic liver disease.

Cardiovascular outcomes

• Kosiborod et al., 2024 (JACC Heart Fail, PMID 39453356) — the rationale and design paper for the SYNCHRONIZE cardiovascular outcomes trial. A design paper reports what a trial intends to measure, which is precisely the kind of statement this page is built to carry.

No outcome figures from any of these appear here. The page records what was investigated, in whom, and by whom — not what any endpoint returned, and nothing a reader should expect.

Research models, evidence status, and what is not established

What is established: the molecule’s preclinical pharmacology and the biomarker evidence that both receptor arms are engaged in vivo (Zimmermann 2022, Thomas 2024); a candidate-selection rationale published in the open literature, which is more transparency than most compounds in this catalogue offer; and randomised trials across obesity, type 2 diabetes and liver disease, conducted by the manufacturer and published in peer-reviewed journals.

What is not established: survodutide is investigational — no regulator has evaluated it as a medicine, so nothing about it has the status of an approved indication. Much of the mechanistic detail above comes from mouse models (diet-induced obese and db/db mice, knockout and reporter strains), and a mouse result is a mouse result. The SYNCHRONIZE cardiovascular trial is, at the design paper cited, described rather than reported. And nothing is established about a research-grade powder: the trials used a manufactured pharmaceutical under medical supervision. This page reports no outcome, makes no efficacy or benefit claim, gives no dosing guidance, and describes material not for human or veterinary use.

How to verify this compound yourself

For a large acylated peptide, identity and purity are established by two orthogonal analytical methods, both reported on a per-batch Certificate of Analysis:

• HPLC purity — reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of the chromatogram. Acylated peptides are strongly retained on reversed-phase columns, and a des-acyl impurity typically elutes well before the target rather than co-eluting with it.
• Mass-spec identity — mass spectrometry confirms the measured mass against the expected molecular weight (≈ 4232 Da). For a peptide of this size, single-residue deletions shift the mass by only a fraction of a percent, so resolution and calibration matter as much as the number itself.
• Endotoxin / sterility — where tested, separate quality attributes reported independently of chemical purity.

An additional point specific to this molecule: survodutide has close structural analogues that were profiled alongside it (BI 456908, BI 456897) and it is easily confused in ordering with the other GCGR/GLP-1R dual agonist, mazdutide. Identity confirmation against the expected mass is therefore not a formality here. See how to read a COA, how to verify peptide purity, and how to spot a fake COA; check the exact batch on the self-serve verify tool.

Research-grade sourcing and verification

Survodutide is not held in Cellworks stock. It appears in the sourcing catalogue as available to order: our supplier lists it, we have not bought it, and sourcing takes roughly two to three weeks. No price is quoted until availability is confirmed, and there is no cart button for it.

Anything sourced this way is a laboratory research reagent with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spectrometry identity. It is not the investigational medicinal product used in the trials cited above and is not for human use.

Frequently asked questions

Literature cited

1. Zimmermann T, Thomas L, Baader-Pagler T, et al. “BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.” Mol Metab. 2022;66:101633. PMID 36356832. pubmed.ncbi.nlm.nih.gov/36356832.
2. Thomas L, Martel E, Rist W, et al. “The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.” Diabetes Obes Metab. 2024;26(6):2368–2378. PMID 38560764. pubmed.ncbi.nlm.nih.gov/38560764.
3. le Roux CW, Steen O, Lucas KJ, et al. “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” Lancet Diabetes Endocrinol. 2024;12(3):162–173. PMID 38330987. pubmed.ncbi.nlm.nih.gov/38330987.
4. Blüher M, Rosenstock J, Hoefler J, et al. “Dose-response effects on HbA_1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes.” Diabetologia. 2024;67(3):470–482. PMID 38095657. pubmed.ncbi.nlm.nih.gov/38095657.
5. Sanyal AJ, Bedossa P, Fraessdorf M, et al. “A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.” N Engl J Med. 2024;391(4):311–319. PMID 38847460. pubmed.ncbi.nlm.nih.gov/38847460.
6. Kosiborod MN, Platz E, Wharton S, et al. “Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.” JACC Heart Fail. 2024;12(12):2101–2109. PMID 39453356. pubmed.ncbi.nlm.nih.gov/39453356.
7. Kaplan LM, Startseva E, le Roux CW, et al. “Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.” Nat Med. 2026. PMID 42252333. pubmed.ncbi.nlm.nih.gov/42252333.
8. National Center for Biotechnology Information. “PubChem Compound Summary for CID 171378821, Survodutide.” pubchem.ncbi.nlm.nih.gov/compound/171378821 (formula, mass, CAS 2805997-46-8).